Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of this year. In contrast, its closest peer, Eli Lilly stock is down 15% over this period.

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00, and a low estimate of $105.00. A 8.65% drop is evident in the current average compared to the previous average price target of $159.00.

Shares in Ozempic maker Novo Nordisk tumbled after an experimental anti-obesity shot fell short of expectations. The shares fell more than 20% in Copenhagen, closing at their lowes

Novo Nordisk (NVO) and Eli Lilly (LLY), the undisputed leaders in the global obesity drug market, saw their stocks heading in opposite directions later this week after the former disappointed investors with its next-gen weight loss candidate,

Novo Nordisk A/S (CPH: NOVO-B) is being punished this morning after posting a disappointing update related to CagriSema. The pharmaceutical behemoth said its experimental weight-loss treatment helped patients lower their weight by 22.